{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:09:37Z","timestamp":1790845777936,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T00:00:00Z","timestamp":1482451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/leu.2016.380","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T15:40:40Z","timestamp":1482594040000},"page":"1915-1921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":295,"title":["Trends in overall survival and costs of multiple myeloma, 2000\u20132014"],"prefix":"10.1038","volume":"31","author":[{"given":"R","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Abouzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bonafede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Cosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,23]]},"reference":[{"key":"BFleu2016380_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Seigel","year":"2016","unstructured":"Seigel RL, Miller KD, Jemal A . Cancer Statistics. 2016 CA Cancer J Clin 2016; 66: 7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"BFleu2016380_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF et al SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD. 2016 http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html Accessed 13 June 2016."},{"key":"BFleu2016380_CR3","unstructured":"Multiple Myeloma Complications, 2012. http:\/\/www.themmrf.org\/multiple-myeloma\/multiple-myeloma-complications . Accessed June 2016."},{"key":"BFleu2016380_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/asheducation-2013.1.488","volume":"2013","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, San Miguel JF . How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program 2013; 2013: 488\u2013495.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFleu2016380_CR5","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962\u20132972.","journal-title":"Blood"},{"key":"BFleu2016380_CR6","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMct0805626","volume":"360","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Moreau P . Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360: 2645\u20132654.","journal-title":"N Engl J Med"},{"key":"BFleu2016380_CR7","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","volume":"31","author":"JL Warren","year":"2013","unstructured":"Warren JL, Harlan LC, Stevens J, Little RF, Abel GA . Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol 2013; 31: 1984\u20131989.","journal-title":"J Clin Oncol"},{"key":"BFleu2016380_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFleu2016380_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFleu2016380_CR10","unstructured":"Beacon TM . Articles tagged with: FDA Approval, 2016. http:\/\/www.myelomabeacon.com\/tag\/fda-approval\/ . Accessed 13 June 2016."},{"key":"BFleu2016380_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song X, Cong Z, Wilson K . Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin 2016; 32: 95\u2013103.","journal-title":"Curr Med Res Opin"},{"key":"BFleu2016380_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","volume":"18","author":"A Teitelbaum","year":"2013","unstructured":"Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ . Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist 2013; 18: 37\u201345.","journal-title":"Oncologist"},{"key":"BFleu2016380_CR13","doi-asserted-by":"publisher","first-page":"e0147381","DOI":"10.1371\/journal.pone.0147381","volume":"11","author":"E Willenbacher","year":"2016","unstructured":"Willenbacher E, Weger R, Rochau U, Siebert U, Willenbacher W . Real-world use of 3rd line therapy for multiple myeloma in austria: an austrian myeloma registry (amr) analysis of the therapeutic landscape and clinical outcomes prior to the use of next generation myeloma therapeutics. PLoS One 2016; 11: e0147381.","journal-title":"PLoS One"},{"key":"BFleu2016380_CR14","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28: 2259\u20132266.","journal-title":"J Clin Oncol"},{"key":"BFleu2016380_CR15","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122\u20131128.","journal-title":"Leukemia"},{"key":"BFleu2016380_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/JCO.2006.08.9805","volume":"25","author":"SD Ramsey","year":"2007","unstructured":"Ramsey SD . How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States. J Clin Oncol 2007; 25: 175\u2013179.","journal-title":"J Clin Oncol"},{"key":"BFleu2016380_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","volume":"18","author":"Jr Garrison LP","year":"2013","unstructured":"Garrison Jr LP, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K et al. The cost-effectiveness of initial treatment of multiple myeloma in the US with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Oncologist 2013; 18: 27\u201336.","journal-title":"Oncologist"},{"key":"BFleu2016380_CR18","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1182\/blood.V122.21.5604.5604","volume":"122","author":"A Berger","year":"2013","unstructured":"Berger A, Bornheimer R, Binder G, Nagarwala Y . Cost-effectiveness of lenalidomide and bortezomib in patients with previously untreated multiple myeloma (MM). Blood 2013; 122: 5604\u20135604.","journal-title":"Blood"},{"key":"BFleu2016380_CR19","doi-asserted-by":"crossref","unstructured":"Rizzo M, Xu Y, Panjabi S, Iheanacho I . A Systematic Literature Review of the Economic Burden in Multiple Myeloma. Paper presented at The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress, 8\u201312 Novermber 2014. Amsterdam, The Netherlands.","DOI":"10.1016\/j.jval.2014.08.2239"},{"key":"BFleu2016380_CR20","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1377\/hlthaff.2014.0826","volume":"33","author":"DP Goldman","year":"2014","unstructured":"Goldman DP, Philipson T . Five myths about cancer care in America. Health Aff (Millwood) 2014; 33: 1801\u20131804.","journal-title":"Health Aff (Millwood)"},{"key":"BFleu2016380_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MLR.0000000000000496","volume":"54","author":"PJ Lin","year":"2016","unstructured":"Lin PJ, Winn AN, Parsons SK, Neumann PJ, Weiss ES, Cohen JT . Linking costs and survival in the treatment of older adults with chronic myeloid leukemia: an analysis of SEER-Medicare Data From 1995 to 2007. Med Care 2016; 54: 380\u2013385.","journal-title":"Med Care"},{"key":"BFleu2016380_CR22","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMp1011024","volume":"363","author":"ME Porter","year":"2010","unstructured":"Porter ME . What is value in health care? N Engl J Med 2010; 363: 2477\u20132481.","journal-title":"N Engl J Med"},{"key":"BFleu2016380_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1365-2141.2012.09124.x","volume":"158","author":"S Ailawadhi","year":"2012","unstructured":"Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T et al. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 2012; 158: 91\u201398.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2016380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016380","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016380.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:06:47Z","timestamp":1684418807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,23]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFleu2016380"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.380","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,23]]},"assertion":[{"value":"9 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors were equally involved in the research, analysis and writing of the paper. Safiya Abouzaid and Kejal Parikh are employees of Celgene Corporation. Machaon Bonafede and Qian Cai are employees of Truven Health Analytics, an IBM company, who received funding from Celgene Corporation to conduct this study. Rafael Fonseca, Leon Cosler and Paul Richardson have served as consultants to Celgene Corporation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}